Sean J Gerrin1, Adam G Sowalsky2,3, Steven P Balk2, Huihui Ye1. 1. Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. 2. Division of Hematology-Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. 3. Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Abstract
INTRODUCTION: High Grade Prostatic Intraepithelial Neoplasia (HGPIN) is the putative precursor lesion to prostatic adenocarcinoma (PCa), but the precise relationship between HGPIN and PCa remains unclear. METHODS: We performed a molecular case study in which we studied mutation profiles of six tumor-associated HGPIN lesions in a single case of TMPRSS2:ERG fusion positive Gleason score 7 PCa that we had previously mapped for somatic mutations in adjacent Gleason patterns 3 and 4 foci, using microdissection and targeted deep-sequencing. RESULTS: A total of 32 tumor-specific mutated sites were successfully amplified and sequenced, including 25 truncal mutations and 7 mutations that were specific to either the Gleason pattern 3 or pattern 4 foci. All six HGPIN foci shared the same tumor-specific TMPRSS2:ERG fusion breakpoint, establishing that they were all clonally related to the adjacent invasive tumor. Among the 32 gene targets mutated in the invasive tumor, only mutation of the OR2AP1 gene, a truncal mutation, was found in a single focus of HGPIN. The remaining gene targets that were successfully sequenced were wild-type in all other HGPIN foci. DISCUSSION: This study demonstrates the feasibility of targeted mutation profiling of HGPIN lesions, which will be important to understand PCa tumorigenesis. The results in this case, showing a remarkable absence of truncal mutations in HGPIN lesions bearing the tumor-specific ERG fusion, indicate HGPIN lesions may be relatively stable genetically and argue against a stepwise clonal evolution model of HGPIN to PCa. Prostate 76:1227-1236, 2016.
INTRODUCTION: High Grade Prostatic Intraepithelial Neoplasia (HGPIN) is the putative precursor lesion to prostatic adenocarcinoma (PCa), but the precise relationship between HGPIN and PCa remains unclear. METHODS: We performed a molecular case study in which we studied mutation profiles of six tumor-associated HGPIN lesions in a single case of TMPRSS2:ERG fusion positive Gleason score 7 PCa that we had previously mapped for somatic mutations in adjacent Gleason patterns 3 and 4 foci, using microdissection and targeted deep-sequencing. RESULTS: A total of 32 tumor-specific mutated sites were successfully amplified and sequenced, including 25 truncal mutations and 7 mutations that were specific to either the Gleason pattern 3 or pattern 4 foci. All six HGPIN foci shared the same tumor-specific TMPRSS2:ERG fusion breakpoint, establishing that they were all clonally related to the adjacent invasive tumor. Among the 32 gene targets mutated in the invasive tumor, only mutation of the OR2AP1 gene, a truncal mutation, was found in a single focus of HGPIN. The remaining gene targets that were successfully sequenced were wild-type in all other HGPIN foci. DISCUSSION: This study demonstrates the feasibility of targeted mutation profiling of HGPIN lesions, which will be important to understand PCa tumorigenesis. The results in this case, showing a remarkable absence of truncal mutations in HGPIN lesions bearing the tumor-specific ERG fusion, indicate HGPIN lesions may be relatively stable genetically and argue against a stepwise clonal evolution model of HGPIN to PCa. Prostate 76:1227-1236, 2016.
Authors: Tarek A Bismar; Maisa Yoshimoto; Robin T Vollmer; Qiuli Duan; Matthew Firszt; Jacques Corcos; Jeremy A Squire Journal: BJU Int Date: 2011-02 Impact factor: 5.588
Authors: Jonathan I Epstein; Lars Egevad; Mahul B Amin; Brett Delahunt; John R Srigley; Peter A Humphrey Journal: Am J Surg Pathol Date: 2016-02 Impact factor: 6.394
Authors: Stephen J Murphy; Robert J Karnes; Farhad Kosari; B Edgardo R Parilla Castellar; Benjamin R Kipp; Sarah H Johnson; Simone Terra; Faye R Harris; Geoffrey C Halling; Janet L Schaefer Klein; Aqsa Nasir; Eric Bergstrahl; Laureano J Rangel; William R Sukov; George Vasmatzis; John C Cheville Journal: Mod Pathol Date: 2015-11-27 Impact factor: 7.842
Authors: Kyung Park; James T Dalton; Ramesh Narayanan; Christopher E Barbieri; Michael L Hancock; David G Bostwick; Mitchell S Steiner; Mark A Rubin Journal: J Clin Oncol Date: 2013-12-02 Impact factor: 44.544
Authors: H Artee Luchman; Hallgrimur Benediktsson; Michelle L Villemaire; Alan C Peterson; Frank R Jirik Journal: PLoS One Date: 2008-12-15 Impact factor: 3.240
Authors: Scott Wilkinson; Huihui Ye; Fatima Karzai; Stephanie A Harmon; Nicholas T Terrigino; David J VanderWeele; John R Bright; Rayann Atway; Shana Y Trostel; Nicole V Carrabba; Nichelle C Whitlock; Stephanie M Walker; Rosina T Lis; Houssein Abdul Sater; Brian J Capaldo; Ravi A Madan; James L Gulley; Guinevere Chun; Maria J Merino; Peter A Pinto; Daniela C Salles; Harsimar B Kaur; Tamara L Lotan; David J Venzon; Peter L Choyke; Baris Turkbey; William L Dahut; Adam G Sowalsky Journal: Eur Urol Date: 2021-03-27 Impact factor: 20.096
Authors: Levent Trabzonlu; Ibrahim Kulac; Qizhi Zheng; Jessica L Hicks; Michael C Haffner; William G Nelson; Karen S Sfanos; Onur Ertunc; Tamara L Lotan; Christopher M Heaphy; Alan K Meeker; Srinivasan Yegnasubramanian; Angelo M De Marzo Journal: Cold Spring Harb Perspect Med Date: 2019-04-01 Impact factor: 6.915
Authors: Gaelle Fiard; Vasilis Stavrinides; Emma S Chambers; Susan Heavey; Alex Freeman; Rhys Ball; Arne N Akbar; Mark Emberton Journal: Nat Rev Urol Date: 2021-07-22 Impact factor: 14.432